Home Covid-19 Updates Triple antiviral drug shows early promise in COVID-19 trial

Triple antiviral drug shows early promise in COVID-19 trial



The Lancet medical journal published findings, that showed that on average people who used the triple drug within five days the virus in them was no longer detectable but however those who were in the control group the virus was not longer detectable between 7 days and 12 days.
A triple drug is a mixture of antiviral medicines the drug helped relieve patients from mild and severe symptoms of the COVID-19 infection and quickly minimised the viral load in the body, according to results of a small trial in Hong Kong.

The trial, which was conducted on127 patients, made a comparison between those who were given the combination drug made up of the HIV medicine lopinavir–ritonavir, the hepatitis drug ribavirin, and the multiple sclerosis treatment interferon beta and a control group which was only given the HIV drug.

“Our trial shows that early treatment of minimum to moderate COVID-19 using a triple combination of antiviral drugs may greatly decrease the amount of virus in a patient’s body, ease’s symptoms, and minimize the risk to health-care workers,” said Kwok-Yung Yuen, a professor at the University of Hong Kong who co-led the research.

He said the decrease in risk to health workers would be attributed to the combination drug’s effect in minimising ‘viral shedding’ which is when the virus can be noticed and potentially transmissible.

In the trial, all patients received standard hospital care which is required, inclusive of ventilation support, dialysis support, antibiotics and corticosteroids.

Kowk-Yung Yuen said the results were “motivating”, but that the triple drug’s effect now need to be tested on a larger group of patients and also on people with more serious COVID-19 illness.

Independent professionals agreed that the results were positive, but said bigger and more detailed studies would be required.

This certainly justifies the suggestion of adding interferon beta to the list of originally, evidence-based, promising treatments to be conducted on further randomised trials,” said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine.

He said that many years of experience in treating the human immunodeficiency virus (HIV) that causes AIDS have proved that it is best cured with combinations of various drugs “and this could also be the same with COVID-19”.